|

Extracellular Vesicle Micro RNA Profiling in Congenital Heart Disease: Fetal-Maternal Regulation in Neonatal Thrombosis

RECRUITINGSponsored by Boston Children's Hospital
Actively Recruiting
SponsorBoston Children's Hospital
Started2024-10-31
Est. completion2026-12-01
Eligibility
Age1 Day – 7 Days
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT06434207

Summary

Newborns with congenital heart disease (CHD) are at increased risk of developing postpartum and postoperative blood clots after cardiac surgery. The molecular mechanisms that are responsible for the clotting profile predisposing children to blood clots in the early stages of life are currently not well described. The goal of this proposal is to prospectively collect plasma samples from ten (10) neonates with antenatal diagnosis of severe congenital heart disease (CHD) to better understand mechanisms responsible for abnormal clotting in the perioperative period.

Eligibility

Age: 1 Day – 7 DaysHealthy volunteers accepted
Inclusion Criteria:

* All neonates with a diagnosis of severe Congenital Heart Disease undergoing surgery at Boston Children's Hospital in the first week of life

Exclusion Criteria:

* None

Conditions4

Congenital Heart DiseaseHeart DiseaseSingle-ventricleThrombosis

Locations1 site

Boston Children's Hospital
Boston, Massachusetts, 02115
Jocelyn Booth, BSN857-218-4585jocelyn.booth@childrens.harvard.edu

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.